Total Payments
$163,565
2024 Payments
$92,258
Companies
13
Transactions
120
Medicare Patients
1,836
Medicare Billing
$169,084
Payment Breakdown by Category
Consulting$78,220 (47.8%)
Other$66,713 (40.8%)
Travel$15,121 (9.2%)
Food & Beverage$3,512 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $78,220 | 12 | 47.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,713 | 29 | 40.8% |
| Travel and Lodging | $15,121 | 24 | 9.2% |
| Food and Beverage | $3,512 | 55 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $94,308 | 76 | $0 (2024) |
| Polarean, Inc. | $50,246 | 10 | $0 (2024) |
| GlaxoSmithKline, LLC. | $18,052 | 21 | $0 (2024) |
| ANI Pharmaceuticals, Inc. | $209.04 | 1 | $0 (2023) |
| Siemens Medical Solutions USA, Inc. | $166.93 | 1 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $152.49 | 3 | $0 (2019) |
| Genentech USA, Inc. | $117.85 | 1 | $0 (2019) |
| Boston Scientific Corporation | $102.23 | 1 | $0 (2018) |
| United Therapeutics Corporation | $98.36 | 2 | $0 (2024) |
| VIDA Diagnostics, Inc. | $51.62 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $92,258 | 40 | Polarean, Inc. ($50,246) |
| 2023 | $6,503 | 18 | Boehringer Ingelheim Pharmaceuticals, Inc. ($4,978) |
| 2022 | $22,800 | 13 | Boehringer Ingelheim Pharmaceuticals, Inc. ($22,800) |
| 2021 | $27,678 | 25 | Boehringer Ingelheim Pharmaceuticals, Inc. ($27,678) |
| 2020 | $13,577 | 10 | Boehringer Ingelheim Pharmaceuticals, Inc. ($13,565) |
| 2019 | $380.63 | 10 | Boehringer Ingelheim Pharmaceuticals, Inc. ($175.34) |
| 2018 | $317.05 | 3 | AstraZeneca Pharmaceuticals LP ($113.22) |
| 2017 | $51.62 | 1 | VIDA Diagnostics, Inc. ($51.62) |
All Payment Transactions
120 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| 12/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,290.00 | General |
| Category: RESPIRATORY | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $78.84 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $55.65 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $32.46 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $24.35 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $6.96 | General |
| 12/09/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $484.04 | General |
| 12/09/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $110.75 | General |
| 12/03/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $804.05 | General |
| 12/03/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $31.02 | General |
| 12/02/2024 | Polarean, Inc. | XENOVIEW (Drug) | Consulting Fee | Cash or cash equivalent | $9,583.33 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $161.96 | General |
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $90.94 | General |
| 11/14/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 11/01/2024 | Polarean, Inc. | XENOVIEW (Drug) | Consulting Fee | Cash or cash equivalent | $9,583.33 | General |
| Category: Respiratory | ||||||
| 10/17/2024 | Polarean, Inc. | XENOVIEW (Drug) | Travel and Lodging | Cash or cash equivalent | $387.74 | General |
| Category: Respiratory | ||||||
| 10/14/2024 | Polarean, Inc. | XENOVIEW (Drug) | Food and Beverage | Cash or cash equivalent | $39.27 | General |
| Category: Respiratory | ||||||
| 10/07/2024 | Polarean, Inc. | XENOVIEW (Drug) | Travel and Lodging | Cash or cash equivalent | $1,655.90 | General |
| Category: Respiratory | ||||||
| 10/02/2024 | Polarean, Inc. | XENOVIEW (Drug) | Consulting Fee | Cash or cash equivalent | $9,583.33 | General |
| Category: Respiratory | ||||||
| 09/12/2024 | Polarean, Inc. | XENOVIEW (Drug) | Consulting Fee | Cash or cash equivalent | $9,583.33 | General |
| Category: Respiratory | ||||||
| 09/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,320.00 | General |
| 08/08/2024 | Polarean, Inc. | XENOVIEW (Drug) | Consulting Fee | Cash or cash equivalent | $9,583.33 | General |
| Category: Respiratory | ||||||
| 08/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $27.18 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 675 | 780 | $180,691 | $41,031 |
| 2022 | 13 | 415 | 550 | $127,803 | $33,782 |
| 2021 | 12 | 406 | 602 | $186,722 | $54,203 |
| 2020 | 11 | 340 | 454 | $128,606 | $40,068 |
Total Patients
1,836
Total Services
2,386
Medicare Billing
$169,084
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 70 | 113 | $29,953 | $10,268 | 34.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 24 | 53 | $37,184 | $8,598 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 63 | 82 | $14,990 | $5,648 | 37.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 38 | $17,075 | $4,959 | 29.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $5,760 | $2,233 | 38.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 22 | $7,362 | $2,179 | 29.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 26 | 31 | $5,552 | $1,871 | 33.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 14 | 15 | $3,250 | $1,529 | 47.0% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 99 | 100 | $24,072 | $902.28 | 3.7% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 117 | 120 | $15,890 | $724.48 | 4.6% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 109 | 109 | $7,971 | $724.15 | 9.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 12 | 14 | $1,925 | $703.64 | 36.6% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 17 | 18 | $2,178 | $306.36 | 14.1% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 26 | 26 | $6,283 | $199.10 | 3.2% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 21 | 21 | $1,246 | $187.14 | 15.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 75 | 160 | $39,264 | $12,207 | 31.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 30 | 52 | $31,600 | $8,719 | 27.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 61 | 81 | $12,537 | $5,305 | 42.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $11,061 | $3,452 | 31.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 26 | $4,539 | $1,412 | 31.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 11 | 11 | $1,881 | $597.22 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 12 | $1,581 | $561.73 | 35.5% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 55 | 55 | $1,654 | $375.68 | 22.7% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 40 | 40 | $10,190 | $368.53 | 3.6% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 43 | 43 | $5,994 | $269.51 | 4.5% |
About Dr. Chase Hall, MD
Dr. Chase Hall, MD is a Pulmonary Disease healthcare provider based in Kansas City, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2011. The National Provider Identifier (NPI) number assigned to this provider is 1659666709.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chase Hall, MD has received a total of $163,565 in payments from pharmaceutical and medical device companies, with $92,258 received in 2024. These payments were reported across 120 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($78,220).
As a Medicare-enrolled provider, Hall has provided services to 1,836 Medicare beneficiaries, totaling 2,386 services with total Medicare billing of $169,084. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease
- Location Kansas City, KS
- Active Since 06/16/2011
- Last Updated 04/23/2020
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1659666709
Products in Payments
- XENOVIEW (Drug) $50,246
- OFEV (Drug) $31,094
- PURIFIED CORTROPHIN GEL (Drug) $209.04
- NAEOTOM Alpha (Device) $166.93
- FASENRA (Drug) $134.14
- ALAIR (Device) $102.23
- BEVESPI AEROSPHERE (Drug) $18.35
- TYVASO (Drug) $17.46
- GLASSIA (Biological) $14.39
- Spin (Device) $12.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Kansas City
Timothy Smith, M.d, M.D
Pulmonary Disease — Payments: $101,990
Pulmonary Disease $101,990
Michael Chacey, Md, MD
Pulmonary Disease — Payments: $21,081
Pulmonary Disease $21,081
Andrea Covey, M.d, M.D
Pulmonary Disease — Payments: $17,994
Pulmonary Disease $17,994
Timothy Saettele, M.d, M.D
Pulmonary Disease — Payments: $13,065
Pulmonary Disease $13,065
Dr. James Ladesich, M.d, M.D
Pulmonary Disease — Payments: $11,691
Pulmonary Disease $11,691
Dr. Michelle Homan, D.o, D.O
Pulmonary Disease — Payments: $9,161
Pulmonary Disease $9,161